Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1351 - 1400 of 1864 results
- Attenuating Regulatory T Cell Induction by TLR Agonists through Inhibition of p38 MAPK Signaling in Dendritic Cells Enhances Their Efficacy as Vaccine Adjuvants and Cancer Immunotherapeutics.
- Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
- Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
- Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer.
- Genetic Delivery of the Murine Equivalent of Bevacizumab (Avastin), an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, to Suppress Growth of Human Tumors in Immunodeficient Mice.
- A clinical study assessing the tolerability and biological effects of infliximab, a TNF-{alpha} inhibitor, in patients with advanced cancer.
- Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
- Intra-vaginal immunization of mice with recombinant Salmonellae expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.
- Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.
- Sensitive detection of tumor marker CA15-3 in human serum by capillary electrophoretic immunoassay with chemiluminescence detection.
- Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule.
- A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.
- Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
- 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy.
- IFN-beta-Dependent Inhibition of Tumor Growth by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA).
- Identification of Breast Cancer Peptide Epitopes Presented by HLA-A*0201.
- Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma.
- A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker.
- Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
- Targeting the TCR signaling checkpoint: a therapeutic strategy to reactivate memory T cells in the tumor microenvironment.
- Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.
- Epigenetic control of MHC-II expression in tumor-associated macrophages by decoy receptor 3.
- Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
- Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
- VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
- Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
- Virulizin((R)) induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors.
- Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma.
- Potent Antitumor Efficacy of ST13 for Colorectal Cancer Mediated by Oncolytic Adenovirus via Mitochondrial Apoptotic Cell Death.
- Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
- Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice.
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
- Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer.
- Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer.
- Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model.
- Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
- Inhibition of IGF receptor signaling and hepatoma cell growth by an antibody to ligand oligopeptide of receptor.
- Thymostimulin in advanced hepatocellular carcinoma: a phase II trial.
- Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
- Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells.
- Targeting activity of a TCR/IL-2 fusion protein against established tumors.
- Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
- Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers.
- A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
- Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
- An effective vaccine strategy protective against antigenically distinct tumor variants.
- Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
- Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11.
- Custom designing therapeutic cancer vaccines: Delivery of immunostimulatory molecule adjuvants by protein transfer.
- Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.